Tid Tittel Kategori Vedlegg
08.04.2026
11:25
 Zelluna ASA - Disclosure of voting rights of Annual General Meeting STORAKSJONÆR AKS -
27.03.2026
10:01
 Zelluna ASA - Mandatory notification of trade INSIDEHANDEL INS
1
26.03.2026
15:28
 Zelluna to host Capital Markets Update 2026 -
1
26.03.2026
08:57
 Zelluna ASA [ZLNA]: Notice of Annual General Meeting on 23 April 2026 -
6
25.03.2026
07:00
 Zelluna ASA [ZLNA]: Annual Report 2025 RAPPORT RAP
2
09.03.2026
08:00
 Zelluna inngår samarbeid med Etcembly for AI-drevet TCR-utvikling - -
09.03.2026
08:00
 Zelluna announces collaboration with Etcembly for AI-enabled TCR engineering - -
20.02.2026
14:30
 Zelluna mottar UK MHRA og etisk godkjenning for oppstart av ZIMA-101 første-i-menneske klinisk studie - -
20.02.2026
14:30
 Zelluna Receives UK MHRA and Ethics Approval to Initiate ZIMA-101 First-in-Human Clinical Trial - -
12.02.2026
07:00
 Zelluna ASA: Fjerde kvartal 2025 - Viktig regulatorisk milepæl oppnådd med CTA-innlevering -
2
12.02.2026
07:00
 Zelluna ASA: Fourth Quarter 2025 - Key regulatory milestone achieved with CTA Submission -
2
11.02.2026
08:00
 Zelluna inngår avtale med Medpace om første kliniske studie - pasientdata ventes fra medio 2026 - -
11.02.2026
08:00
 Zelluna selects Medpace as CRO for ZIMA-101 first-in-human clinical trial - -
05.02.2026
13:30
 Zelluna ASA - Grant of Share Options - -
05.02.2026
09:30
 Zelluna ASA: Invitation to Fourth Quarter 2025 Results Webcast Presentation - -
03.02.2026
08:00
 Zelluna utnevner Emilie Gauthy til Chief Technology Officer - -
03.02.2026
08:00
 Zelluna promotes Emilie Gauthy to Chief Technology Officer - -
15.01.2026
12:22
 Zelluna ASA: Approval and publication of prospectus - -
17.12.2025
17:26
 Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World's First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours - -
17.12.2025
17:26
 Zelluna har nådd en viktig milepæl og innleverer søknad om klinisk studie i Storbritannia for første studie på mennesker av ZI-MA4-1 (ZIMA-101), verdens første MAGE-A4-rettede TCR-NK celleterapi for solide kreftformer. - -
16.12.2025
12:36
 Zelluna Publishes Compelling Preclinical Data for ZI-MA4-1, the World's First MAGE-A4-Targeting TCR-NK Therapy for Solid Tumours - -
12.12.2025
13:02
 Zelluna Completes First GMP Batch of ZI-MA4-1, a Novel TCR-NK Cell Therapy, to Treat Patients in Upcoming First-in-Human Trial - -
09.12.2025
09:36
 Zelluna ASA: Cancellation of subsequent repair offering - -
08.12.2025
18:36
 Zelluna ASA - Mandatory notification of trade STORAKSJONÆR AKS
1
08.12.2025
13:52
 Zelluna ASA: New share capital registered - -